Treatment de-escalation for HPV-driven oropharyngeal cancer: Where do we stand?

Citation data:

Clinical and translational radiation oncology, ISSN: 2405-6308, Vol: 8, Page: 4-11

Publication Year:
2018
Usage 1
Abstract Views 1
Captures 37
Readers 37
Mentions 1
References 1
Social Media 40
Tweets 40
Citations 2
Citation Indexes 2
PMID:
29594236
DOI:
10.1016/j.ctro.2017.10.005
Author(s):
Mirghani, Haitham; Blanchard, Pierre
Publisher(s):
Elsevier BV
Most Recent Tweet View All Tweets
review description
HPV-driven oropharyngeal cancers have significantly better survival rates than tobacco and alcohol induced head and neck cancers. As HPV-positive patients are younger, healthier and far more likely to survive their disease, long-term treatment side effects are becoming a major issue. This has led the scientific and medical community to reassess the current treatment protocols in order to develop less toxic strategies while maintaining good oncological outcomes. In this article, we discuss the ongoing treatment de-escalation trials and highlight the issues raised by these studies.